While multiple clinical trials have suggested that a high baseline tumor expression of ERCC1 protein or mRNA [21, 22, 41] may serve as a biomarker for relative resistance to platinum compounds, no studies have examined the relationship between ERCC1 induction in response to oxaliplatin treatment and patient outcome. This evidence concerns the gene ERCC1 and neoplasm.